LURE, France--(BUSINESS WIRE)--Regulatory News: Vétoquinol (Paris:VETO) announces the installation of its first decentralized research and development division in Canada. This R&D center is being set up to enhance the performance of the existing line of pharmaceutical products and the local innovation process, as well as to enable the company to respond even more precisely to the specific needs of the North American market. The research work carried out in Saint-Hyacinthe may then be extended to medication sold throughout North America.
